Targeting Prostate Cancer Stem Cells with Alpha-Particle Therapy

Area of Science:

• Oncology
• Radiopharmaceutical Therapy
• Molecular Imaging and Therapy

Background:

• Traditional targeted therapy relies on homogenous antigen expression, which may miss resistant cancer stem cells (CSCs).
• Cancer stem cells (CSCs) drive tumor recurrence and resistance to conventional therapies, including radioresistance.
• Prostate cancer (PCa) recurrence is often linked to therapy-resistant CSCs that evade standard treatments.

Purpose of the Study:

• To evaluate the potential of targeted alpha-particle therapy for eradicating cancer stem cells (CSCs) in prostate cancer (PCa).
• To discuss the parameters, advantages, and disadvantages of using alpha-particle emitting radionuclides for PCa treatment.

Main Methods:

• Review of alpha-particle characteristics and their suitability for targeted cancer therapy.
• Analysis of CSC biology and their role in treatment resistance and tumor recurrence.
• Evaluation of alpha-particle emitting radionuclides for targeting CSCs in prostate cancer.

Main Results:

• Alpha particles offer high localized energy deposition, ideal for destroying small tumor cell clusters and individual CSCs.
• The intense DNA damage caused by alpha particles is effective against radioresistant CSCs.
• Targeting CSCs with alpha-particle therapy may overcome resistance to conventional treatments like androgen deprivation.

Conclusions:

• Targeted alpha-particle therapy presents a promising strategy to eliminate therapy-resistant CSCs in prostate cancer.
• This approach could potentially cure PCa or significantly prolong survival in patients with recurrent or advanced disease.
• Further research and consideration of specific parameters are crucial for the clinical application of alpha-particle therapy in PCa.